248 related articles for article (PubMed ID: 30500863)
1. Beyond interferon side effects: What residual barriers exist to DAA hepatitis C treatment for people who inject drugs?
Madden A; Hopwood M; Neale J; Treloar C
PLoS One; 2018; 13(11):e0207226. PubMed ID: 30500863
[TBL] [Abstract][Full Text] [Related]
2. The politics of place(ment): problematising the provision of hepatitis C treatment within opiate substitution clinics.
Rance J; Newland J; Hopwood M; Treloar C
Soc Sci Med; 2012 Jan; 74(2):245-53. PubMed ID: 22133583
[TBL] [Abstract][Full Text] [Related]
3. The Potential Reach of Opioid Substitution Settings to Deliver HCV Care to People Who Inject Drugs in Australia.
Butler K; Day C; Dietze P; Bruno R; Alati R; Burns L
J Subst Abuse Treat; 2015 Nov; 58():90-4. PubMed ID: 26117080
[TBL] [Abstract][Full Text] [Related]
4. "Everybody living with a chronic disease is entitled to be cured": Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs.
Goodyear T; Ti L; Carrieri P; Small W; Knight R
Int J Drug Policy; 2020 Jul; 81():102766. PubMed ID: 32416525
[TBL] [Abstract][Full Text] [Related]
5. Uptake of direct acting antiviral therapies for the treatment of hepatitis C virus among people who inject drugs in a universal health-care system.
Butler K; Larney S; Day CA; Burns L
Drug Alcohol Rev; 2019 Mar; 38(3):264-269. PubMed ID: 30548702
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study.
Bajis S; Grebely J; Hajarizadeh B; Applegate T; Marshall AD; Ellen Harrod M; Byrne J; Bath N; Read P; Edwards M; Gorton C; Hayllar J; Cock V; Peterson S; Thomson C; Weltman M; Jefferies M; Wood W; Haber P; Ezard N; Martinello M; Maher L; Dore GJ;
J Viral Hepat; 2020 Mar; 27(3):281-293. PubMed ID: 31698545
[TBL] [Abstract][Full Text] [Related]
7. Personal, provider and system level barriers and enablers for hepatitis C treatment in the era of direct-acting antivirals: Experiences of patients who inject drugs accessing treatment in general practice settings in Australia.
Heard E; Smirnov A; Massi L; Selvey LA
J Subst Abuse Treat; 2021 Aug; 127():108460. PubMed ID: 34134878
[TBL] [Abstract][Full Text] [Related]
8. Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study.
Midgard H; Hajarizadeh B; Cunningham EB; Conway B; Backmund M; Bruggmann P; Bruneau J; Bourgeois S; Dunlop A; Foster GR; Hellard M; Robaeys G; Thurnheer MC; Weltman M; Amin J; Marks PS; Quiene S; Dore GJ; Dalgard O; Grebely J;
Int J Drug Policy; 2017 Sep; 47():230-238. PubMed ID: 28633998
[TBL] [Abstract][Full Text] [Related]
9. Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs.
Day E; Broder T; Bruneau J; Cruse S; Dickie M; Fish S; Grillon C; Luhmann N; Mason K; McLean E; Trooskin S; Treloar C; Grebely J
Int J Drug Policy; 2019 Apr; 66():87-93. PubMed ID: 30743093
[TBL] [Abstract][Full Text] [Related]
10. The impact of universal access to direct-acting antiviral therapy on the hepatitis C cascade of care among individuals attending primary and community health services.
Traeger MW; Pedrana AE; van Santen DK; Doyle JS; Howell J; Thompson AJ; El-Hayek C; Asselin J; Polkinghorne V; Membrey D; Bramwell F; Carter A; Guy R; Stoové MA; Hellard ME;
PLoS One; 2020; 15(6):e0235445. PubMed ID: 32603349
[TBL] [Abstract][Full Text] [Related]
11. Initial outcomes of integrated community-based hepatitis C treatment for people who inject drugs: Findings from the Queensland Injectors' Health Network.
Morris L; Smirnov A; Kvassay A; Leslie E; Kavanagh R; Alexander N; Davey G; Williams O; Gilks C; Najman J
Int J Drug Policy; 2017 Sep; 47():216-220. PubMed ID: 28666635
[TBL] [Abstract][Full Text] [Related]
12. Patient and provider perceived barriers and facilitators to direct acting antiviral hepatitis C treatment among priority populations in high income countries: A knowledge synthesis.
Amoako A; Ortiz-Paredes D; Engler K; Lebouché B; Klein MB
Int J Drug Policy; 2021 Oct; 96():103247. PubMed ID: 33853727
[TBL] [Abstract][Full Text] [Related]
13. Prevention, treatment and care of hepatitis C virus infection among people who inject drugs.
Bruggmann P; Grebely J
Int J Drug Policy; 2015 Feb; 26 Suppl 1():S22-6. PubMed ID: 25245939
[TBL] [Abstract][Full Text] [Related]
14. Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis.
Hajarizadeh B; Cunningham EB; Reid H; Law M; Dore GJ; Grebely J
Lancet Gastroenterol Hepatol; 2018 Nov; 3(11):754-767. PubMed ID: 30245064
[TBL] [Abstract][Full Text] [Related]
15. Barriers to access to hepatitis C treatment with direct-acting antivirals in people who inject drugs in the community setting.
Yela E; Solé N; Puig L; López Gallegos D; Clua-García R
Harm Reduct J; 2024 Apr; 21(1):88. PubMed ID: 38678266
[TBL] [Abstract][Full Text] [Related]
16. Untreated alcohol use disorder in people who inject drugs (PWID) in France: a major barrier to HCV treatment uptake (the ANRS-FANTASIO study).
Barré T; Marcellin F; Di Beo V; Delorme J; Rojas Rojas T; Mathurin P; Protopopescu C; Bailly F; Coste M; Authier N; Carrieri MP; Rolland B
Addiction; 2020 Mar; 115(3):573-582. PubMed ID: 31595554
[TBL] [Abstract][Full Text] [Related]
17. Directly observed hepatitis C treatment with opioid substitution therapy in community pharmacies: A qualitative study.
Gunn J; Higgs P
Res Social Adm Pharm; 2020 Sep; 16(9):1298-1301. PubMed ID: 31003763
[TBL] [Abstract][Full Text] [Related]
18. Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals.
Treloar C; Newland J; Rance J; Hopwood M
J Viral Hepat; 2010 Dec; 17(12):839-44. PubMed ID: 20070504
[TBL] [Abstract][Full Text] [Related]
19. Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia.
Keats J; Micallef M; Grebely J; Hazelwood S; Everingham H; Shrestha N; Jones T; Bath N; Treloar C; Dore GJ; Dunlop A;
Int J Drug Policy; 2015 Oct; 26(10):999-1006. PubMed ID: 26275578
[TBL] [Abstract][Full Text] [Related]
20. 'Hep C's like the common cold': understanding barriers along the HCV care continuum among young people who inject drugs.
Skeer MR; Ladin K; Wilkins LE; Landy DM; Stopka TJ
Drug Alcohol Depend; 2018 Sep; 190():246-254. PubMed ID: 30071457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
